These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Protein-based nano-vaccines against SARS-CoV-2: Current design strategies and advances of candidate vaccines. Wang D; Yuan Y; Liu B; Epstein ND; Yang Y Int J Biol Macromol; 2023 May; 236():123979. PubMed ID: 36907305 [TBL] [Abstract][Full Text] [Related]
27. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa. Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842 [TBL] [Abstract][Full Text] [Related]
28. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact on translational nanomedicine. Milane L; Amiji M Drug Deliv Transl Res; 2021 Aug; 11(4):1309-1315. PubMed ID: 33512669 [TBL] [Abstract][Full Text] [Related]
29. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection. Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM Elife; 2022 Jan; 11():. PubMed ID: 35072628 [TBL] [Abstract][Full Text] [Related]
30. Immunogenicity and protective potential of chimeric virus-like particles containing SARS-CoV-2 spike and H5N1 matrix 1 proteins. Chen J; Xu W; Li L; Yi L; Jiang Y; Hao P; Xu Z; Zou W; Li P; Gao Z; Tian M; Jin N; Ren L; Li C Front Cell Infect Microbiol; 2022; 12():967493. PubMed ID: 35923799 [TBL] [Abstract][Full Text] [Related]
31. COVID-19: Coronavirus Vaccine Development Updates. Zhao J; Zhao S; Ou J; Zhang J; Lan W; Guan W; Wu X; Yan Y; Zhao W; Wu J; Chodosh J; Zhang Q Front Immunol; 2020; 11():602256. PubMed ID: 33424848 [TBL] [Abstract][Full Text] [Related]
32. A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants. Jiang L; Driedonks TAP; Jong WSP; Dhakal S; Bart van den Berg van Saparoea H; Sitaras I; Zhou R; Caputo C; Littlefield K; Lowman M; Chen M; Lima G; Gololobova O; Smith B; Mahairaki V; Riley Richardson M; Mulka KR; Lane AP; Klein SL; Pekosz A; Brayton C; Mankowski JL; Luirink J; Villano JS; Witwer KW J Extracell Vesicles; 2022 Mar; 11(3):e12192. PubMed ID: 35289114 [TBL] [Abstract][Full Text] [Related]
33. SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus. Oberemok VV; Laikova KV; Yurchenko KA; Marochkin NA; Fomochkina II; Kubyshkin AV Inflamm Res; 2020 Sep; 69(9):801-812. PubMed ID: 32656668 [TBL] [Abstract][Full Text] [Related]
34. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern. Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895 [TBL] [Abstract][Full Text] [Related]
35. Current vaccine strategies against SARS-CoV-2: Promises and challenges. Kurup D; Myers J; Schnell MJ J Allergy Clin Immunol; 2022 Jul; 150(1):17-21. PubMed ID: 35618046 [TBL] [Abstract][Full Text] [Related]
36. Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population. Bednarski E; Del Rio Estrada PM; DaSilva J; Boukadida C; Zhang F; Luna-Villalobos YA; Rodríguez-Rangel X; Pitén-Isidro E; Luna-García E; Díaz Rivera D; López-Sánchez DM; Tapia-Trejo D; Soto-Nava M; Astorga-Castañeda M; Martínez-Moreno JO; Urbina-Granados GS; Jiménez-Jacinto JA; Serna Alvarado FJ; Enriquez-López YE; López-Arellano O; Reyes-Teran G; Bieniasz PD; Avila-Rios S; Hatziioannou T mBio; 2022 Aug; 13(4):e0084022. PubMed ID: 35735743 [TBL] [Abstract][Full Text] [Related]
37. Preclinical study of a DNA vaccine targeting SARS-CoV-2. Hayashi H; Sun J; Yanagida Y; Otera T; Kubota-Koketsu R; Shioda T; Ono C; Matsuura Y; Arase H; Yoshida S; Nakamaru R; Ju N; Ide R; Tenma A; Kawabata S; Ehara T; Sakaguchi M; Tomioka H; Shimamura M; Okamoto S; Amaishi Y; Chono H; Mineno J; Komatsuno T; Saito Y; Rakugi H; Morishita R; Nakagami H Curr Res Transl Med; 2022 Sep; 70(4):103348. PubMed ID: 35489099 [TBL] [Abstract][Full Text] [Related]
38. Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions. Abulsoud AI; El-Husseiny HM; El-Husseiny AA; El-Mahdy HA; Ismail A; Elkhawaga SY; Khidr EG; Fathi D; Mady EA; Najda A; Algahtani M; Theyab A; Alsharif KF; Albrakati A; Bayram R; Abdel-Daim MM; Doghish AS Biomed Pharmacother; 2023 Jan; 157():113977. PubMed ID: 36370519 [TBL] [Abstract][Full Text] [Related]
39. Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease. Deschambault Y; Lynch J; Warner B; Tierney K; Huynh D; Vendramelli R; Tailor N; Frost K; Sajesh B; LeBlanc K; Layne C; Lin L; Tamming L; Beniac D; Booth S; Carpenter M; Safronetz D; Li X; Kobasa D; Cao J J Virol; 2022 May; 96(9):e0038922. PubMed ID: 35412347 [TBL] [Abstract][Full Text] [Related]
40. DNA origami presenting the receptor binding domain of SARS-CoV-2 elicit robust protective immune response. Oktay E; Alem F; Hernandez K; Girgis M; Green C; Mathur D; Medintz IL; Narayanan A; Veneziano R Commun Biol; 2023 Mar; 6(1):308. PubMed ID: 36959304 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]